RE:RE:RE:Quote from the Baxter Webcast QA"The 64k question is what value does CG put on PMX distribution rights - I.e. discounted future cash flows from sales of PMX starting in 2025 or 2026?"
Exactly MM, how do you put a value on something without even knowing atleast the rough mortality benefit from the crude data? And the only way to get a glimpse at those would be to sign an NDA with Spectral. And the only way Spectral would be willing to sign that NDA and share those numbers, is if it was for negotiating a takeover of themselves not Vantive. So yeah, I think you make a very valid point with your two-pronged negotiations concept.
Either way, Spectral just needs to continue doing the great job they've been doing with enrollment, and find those final 25 patients so that everyone can get a look at the numbers. Who knows, maybe a PE firm that Carlyle Group outbid for Vantive, will have interest in Spectral once they see the mortality benefit numbers and realize that PMX will quickly be adopted into the SOC of Seprtic Shock patients.